Compare Regeneron Pharmaceuticals Inc (REGN) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B), while iShares 1 3 Year Treasury Bond ETF trades at $81.22 (market cap $26.68B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.9× iShares 1 3 Year Treasury Bond ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| REGN | SHY | |
|---|---|---|
Market Cap | $76.14B | $26.68B |
Volume | 500,239 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $852.03 | $83.18 |
52-Week Low | $557.73 | $81.05 |
Typical Hold Time | 107 Days | 63 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
SHY, a US stock, trades at $81.16, up 0.04% on the day. Technical indicators are bearish, with moving averages signaling sell pressure and oscillators neutral. The stock faces resistance and support near $81. Recent corporate actions include dividend payments, with the latest at $0.24 per share. Financial ratios are unavailable in the provided data, limiting fundamental analysis.
The outlook for SHY is cautious due to bearish technical signals and a lack of current fundamental data. Investment opportunities may arise from dividend income, but risks include market volatility and reliance on broader economic conditions. Investors should seek updated financials for a complete assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
